18/11/2026 - Press release
This is the finding of a study published in the journal Diabetes, Obesity and Metabolism, which analysed data from 15,000 participants in the CORDELIA meta-cohort, the largest of its kind in Spain. The data show that people who engage in less physical exercise e gain weight 60% faster than those with high levels of physical activity. At older ages, they also experience more pronounced weight loss. The study analysed changes in participants' body mass index between the ages of 30 and 90 and found that the effects of physical activity are more marked in men
Més informació "Physical activity protects against obesity throughout life"
12/11/2026 - Press release
Implanting antibiotics directly where bone infections are treated in the operating room achieves, in just six days, the same effects as the usual systemic approach with antibiotics administered by injection or orally, a type of treatment lasting between six and twelve weeks. It does so without compromising the patient's recovery and with fewer side effects. This is demonstrated by the results of the international SOLARIO (Short or long antibiotic regimes in orthopaedics) study, which has just been published by the journal The New England Journal of Medicine. The study was led by Oxford University Hospitals, with 25 centres from the United Kingdom, Germany, Austria, Portugal and Spain taking part. Hospital del Mar is the only centre in Spain to have participated.
04/11/2026 - Press release
The study, led by the Cancer Immunotherapy Research Group, a joint research group of the Hospital del Mar Research Institute, the Spanish National Cancer Research Centre (CNIO) and the Hospital 12 de Octubre Research Institute (i+12), has been published in the journal Advanced Science. Researchers have succeeded in activating and regulating the antitumour activity of modified T cells, both in vitro and in mice, through the administration of a drug. The system has demonstrated its effectiveness against both haematological malignancies and solid tumours. This approach could help prevent the toxic effects associated with these therapies, particularly in the treatment of solid tumours.
29/10/2026 - Press release
Cheating in sport through doping is becoming increasingly difficult. And the latest study led by Laboratorio Antidopaje de Cataluña, part of the Hospital del Mar Research Institute (HMRIB), will make it even harder for athletes who seek to improve their performance through fraudulent means. The study, published in the journal Medicine & Science in Sports & Exercise, has validated capillary blood sampling as a tool that is just as effective for detecting potential cases of doping as traditional venous blood sampling.
Més informació "New blood sampling system validated in the fight against doping"
20/10/2026 - Press release
The risk of a repeat suicide attempt is particularly high during the three months following hospital admission for a suicide attempt, according to the results obtained within the SURVIVE project and published in The Lancet Regional Health Europe. The main risk factors are the patient's mental health conditions and history of suicidal behaviour. A high burden of psychotropic medication and experiences of emotional neglect during childhood also play a role. The researchers believe these findings should lead to a reassessment of the follow-up provided to people treated after a suicide attempt, as well as to a more precise identification of their risk factors.
07/10/2026 - Press release
The GLP-1 receptor is a protein that responds to GLP-1, a naturally occurring hormone that regulates blood sugar levels and feelings of satiety. It is therefore the target of some of the most advanced and widely used treatments currently available for type 2 diabetes and obesity, such as Ozempic. For this reason, understanding how the function of this receptor may vary depending on genetic changes affecting it is particularly important. Individuals can naturally carry different genetic variants of the GLP-1 receptor, known as GLP1R variants. The individual risk of developing type 2 diabetes and variability in response to treatment may differ depending on the presence of a particular variant.
09/09/2026 - Press release
This technique identifies tumour mutations for which treatments are available, showing a high level of concordance with the analysis of tumour tissue samples. This makes it a particularly useful alternative when there is insufficient tissue available to carry out comprehensive molecular profiling of the tumour. Published in Clinical Cancer Research, the study analyses the largest cohort described to date, comprising nearly 11,000 patients, and validates the findings in an independent cohort of 126 patients with biliary tract cancer from nine hospitals across Spain.
14/07/2026 - Press release
People who experienced traumatic events during childhood are 1.5 times more likely to develop physical illnesses than the general population. The association is strongest in cases of bullying, physical or sexual abuse, and parental loss or abandonment, according to a study led by the Hospital del Mar Research Institute that analyzed data from 250 published studies on the subject up to April 2025. The findings may help draw attention to the possible causes of a wide range of physical diseases and reinforce efforts to prevent childhood trauma
Més informació "Childhood Trauma Linked to Higher Risk of Developing Physical Disease"
18/06/2026 - Press release
A study in mice by the Hospital del Mar Research Institute and the IIBB-CSIC, published in Science Advances, identifies inhibition of the PARP2 protein as a therapeutic target for treating pancreatic cancer, the third leading cause of cancer death worldwide. The study analyses the role of this protein in tumour development and protection, and describes how its elimination leads to tumour cell death and activation of the immune system. Specifically blocking this protein may be a useful strategy for treating a large number of patients with pancreatic cancer and could even be applicable to other types of tumours.
10/06/2026 - Press release
CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of its Phase IIa clinical trial evaluating its lead first-in-class program, CTH120, in adult males with fragile X syndrome (FXS). CTH120 is a novel small molecule targeting the tropomyosin receptor kinase B (TrkB), a key regulator of neuroplasticity, the brain's ability to form and adapt neural connections. Impaired neuroplasticity is a core pathophysiological feature in neurodevelopmental disorders and contributes to the clinical manifestations observed in conditions such as FXS. FXS is the most common inherited cause of intellectual disability, with an estimated prevalence of approximately 3 per 10,000 individuals.
Servei de Comunicació:
Marta Calsina(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact